A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2
NCT06931028 on ClinicalTrials.gov · last registry update 2025-06-29
Recruiting now, toward 260 participants. Due to report 7 May 2027, alongside 33 other tracked readouts that quarter. Primary outcome, as filed: Change from Baseline in Apnea-Hypopnea Index (AHI). Sponsors move these dates routinely; any movement since this site started watching is listed below. mazdutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended.
- Status
- RECRUITING
- Phase
- P3
- Drug
- mazdutide
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Sponsor type
- Industry
- Enrollment
- 260
- Started
- 2025-06-12
- Primary completion
- 2027-05-07 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change from Baseline in Apnea-Hypopnea Index (AHI)
Conditions studied
Sleep Apnea · Obstructive · Obesity
Every field above is taken directly from the registry record. See all detected changes across the class, or the mazdutide page for this molecule’s full trial and approval history.